Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $120.00 | Underweight | Wells Fargo |
1/4/2024 | $100.00 → $125.00 | In-line → Outperform | Evercore ISI |
LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter ("3Q25") ended December 31, 2024 (amounts in thousands). Third quarter FY 2025 compared to third quarter FY 2024: Revenues increased 17.5%Non-GAAP core organic revenues1 increase was 13.2%Operating income increased 8,725% to $5,779Non-GAAP adjusted operating income excluding unusual items2 increased 13.3% and was 23.5% as a percentage of revenues We operate our business in four divisions: Sterilization and Disinfection Control ("SDC"
LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:00 A.M. Eastern time on Tuesday, February 4, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. CONTACT: Gary Owens, President and
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa", "we", "us", or "our"), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the "Board"), effective January 5, 2024. Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: "We are pleased to welcome Mark to Mesa's Board. Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics. We believe Mark's insights will be pivotal to Mesa
LAKEWOOD, Colo., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) ("Mesa" or the "Company") today announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors ("Board"), effective November 3, 2022. Mr. Ladiwala assumes this newly re-created role as an expansion of his current responsibilities on the Board, on which he has served since October 2021. Mr. Ladiwala was selected for this important role due to the thoughtful leadership and contributions he has made to the Board as well as the exceptional breadth of his professional experience. Mr. Ladiwala said, "I am delighted to accept this leadership role on Mes
LAKEWOOD, Colo., June 27, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its Board of Directors (the "Board"), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022. With Mr. Tripeny's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. Mr. Tripeny is likely to be appointed to the Audit Committee and brings extensive financial experience to the Board. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
SC 13G/A - MESA LABORATORIES INC /CO/ (0000724004) (Subject)
Wells Fargo initiated coverage of Mesa Laboratories with a rating of Underweight and set a new price target of $120.00
Evercore ISI upgraded Mesa Laboratories from In-line to Outperform and set a new price target of $125.00 from $100.00 previously
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
4 - MESA LABORATORIES INC /CO/ (0000724004) (Issuer)
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increa
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024. About Mesa Laboratories, Inc. Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, in
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
8-K - MESA LABORATORIES INC /CO/ (0000724004) (Filer)
10-Q - MESA LABORATORIES INC /CO/ (0000724004) (Filer)